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ABSTRACT
Objective: Bleeding is the most serious complication associated with anticoagulation therapy. The purpose of this study was to estimate the frequency 
of major bleeding related to warfarin and to identify its predictors in patients with atrial fibrillation (AF).
Methods: Patients with AF treated with warfarin at Penang General Hospital in Malaysia were identified according to the international classification 
of disease, Ninth Revision, Clinical Modification (ICD-9). The medical reports of 1611 patients were reviewed, bleeding events were set as primary end 
point which were identified in 313 patients. Demographic and clinical data were retrieved and warfarin therapy-related parameters including dose, 
therapy duration, and prothrombin time-international normalized ratio (PT-INR) were recorded and analyzed using descriptive statistics.
Results: Of the 313 patients, 28 patients with major bleeding events were identified. Gastrointestinal bleeding was the major type of bleeding, which 
accounts for 68% (n = 17) of the cases. The frequency of major bleeding events among all AF patients was 1.7%. High PT-INR value was found in 96.3% 
(n = 28) of the patients, thereby making it the primary predictor of bleeding events. Other predictors including, advanced age, other comorbidities 
such as hypertension and multiple anticoagulation therapy were also observed to be significant.
Conclusion: Lower doses of warfarin are recommended to achieve target PT-INR range similar to that reported previously for Asian populations. 
A regular clinical review for bleeding predictors is essential for maximizing the time spent by the patient taking warfarin in the optimal therapeutic 
range and for making recommended therapy adjustment.
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INTRODUCTION
Atrial fibrillation (AF) is the most common clinically significant 
arrhythmias and is estimated to be responsible for approximately 
15–20% of all strokes [1]. It counts as the main indication for long-
term treatment with warfarin [2]. Anticoagulation therapy with 
warfarin effectively reduces the risk of ischemic stroke associated with 
AF; however, it increases the risk for major bleeding. Clinical studies 
revealed that the risk of intracranial hemorrhage, the most common 
site of bleeding, is as great as that of thromboembolic events which 
warfarin is used to prevent [3,4]. Therefore, optimal use of warfarin 
therapy for AF requires a precise assessment for established risk factors 
of bleeding such as advanced age, hypertension, stroke, alcoholism, and 
malignancy [5]. In addition, rigorous reporting of warfarin-associated 
bleeding is warranted, as patients who bleed often discontinue 
treatment, which put them at a higher risk of thromboembolism [6,7].
The current dosing guidelines emphasize the importance of adjusting 
warfarin dose to maintain the patient’s prothrombin time-international 
normalized ratio (PT-INR) 2–3 [8]. European studies reported major 
bleeding incidence under warfarin therapy for non-valvular AF as 
1.6–2.5% per year with adjusted standard-dose warfarin (PT-INR 
2.0-4.5) [9]. In Japan, a study reported an incidence of major bleeding of 
6.6% per year with adjusted standard-dose warfarin (PT-INR 2.2–3.5) 
and 0% per year with adjusted low-dose warfarin (PT-INR 1.5–2.1) [10], 
suggesting that appropriate control by warfarin therapy might differ 
between populations. In Malaysia, a higher number of stroke cases 
and lower rates of anticoagulant use were reported compared to other 
countries in Europe and South Africa [11]. With the increase of long-
term warfarin therapy, there is a pressing need to identify clinical 
features that raise the risk of severe bleeding complications. The 
purpose of this study was to estimate the frequency of major bleeding 
associated with the use of warfarin and to identify bleeding risk factors 
among patients with AF in Malaysia.
METHODS
Study design and settings
A retrospective study was conducted in Penang General Hospital (PGH), 
a large integrated Healthcare Delivery System located in Penang state 
in northwest of Malaysia. All patients (18 years and older), who had 
been diagnosed with AF and admitted to the hospital with any type of 
bleeding between January 2005 and December 2011, were identified 
using the international classification of disease, Ninth Revision, Clinical 
Modification (ICD-9), as the following, ICD-427.31 (identifies cases 
with AF) ICD-T45.515 (side effects of anticoagulants), and ICD-459.0 
(hemorrhage). In total, there were 313 patients with AF, who presented 
with bleeding, of 1611 patients with AF. This study was approved by 
Medical Research Ethics Committee of the Ministry of Health and by the 
Clinical Research Centre.
Data collection
Demographic data of 313 patients included in the study (e.g., age, 
gender, and race) and clinical characteristic of their disease such as site 
of bleeding (intracranial, gastrointestinal, intraocular, intrarenal, etc.). 
Other medical comorbidities such as Hypertension, stroke, transient 
ischemic attack, diabetes mellitus, myocardial infarction, and congestive 
heart failure; and concomitant drug use, for example, statin and aspirin 
were obtained from admission medical records. Furthermore, warfarin 
dose and duration of therapy, INR measurement closest to the onset 
of symptoms, and other laboratory tests (PT, platelet count, and HGB) 
were recorded. CHADS2 score (congestive heart failure, hypertension, 
age ≥75, diabetes mellitus, and prior stroke or transient ischemic 
attack) was calculated for each patient.
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Definition of major bleeding
It has been established that the definition of major bleeding needs to 
be based on objective criteria, major bleeding events are those which 
result in death, considered as life-threatening and cause chronic 
sequelae or consume major health-care resources. With this in mind, 
the Subcommittee on Control of Anticoagulation of the Scientific and 
Standardization Committee of the International Society on Thrombosis 
and Haemostasis sets the following criteria for major bleeding in non-
surgical patients [12]:
1. Fatal bleeding, and/or
2. Symptomatic bleeding in a critical area or organ, such as intracranial, 
intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, 
or intramuscular with compartment syndrome, and/or
3. Bleeding causing a fall in hemoglobin level of ≥20 g/L (1.24 mmol/L), 
or leading to transfusion of two or more units of whole blood or red 
blood cells.
Statistical analysis
The Statistical Package for the Social Sciences (IBM SPSS statistics 
version 20) Microsoft program was used for data analysis. The type, 
site, and frequency of bleeding events were recorded. Descriptive 
analysis for demographic data and clinical characteristics of patients 
enrolled was conducted. For continuous variable, means and standard 
deviation were used.
RESULTS
A total of 1611 adults (18 and older), who had been diagnosed with AF 
and received healthcare in PGH, were identified. Patients (n=313) had 
adverse effects of bleeding during warfarin therapy were then identified 
using the ICD code. Systematic revision of the medical files revealed 
that 28 patients had major bleeding event at time of admission. The 
frequency of major bleeding events among all AF patients was 1.7%.
In this study, the majority of cases were Malay, followed by Chinese, 
which reflects ethnicities distribution in the state of Penang. In terms 
of gender distribution, two-third of the cases were males (n=17). The 
mean age at the time of bleeding event was 68.8 years. In addition to AF, 
patients had other comorbidities, including hypertension was the most 
frequent 71.4% (n=20) followed by diabetes mellitus 32.1% (n=9). 
Furthermore, all patients were on fibrates, 64% were on statins and 
50% were on antiplatelet, for example, aspirin or clopidogrel.
The CHADS2 scoring system is a simple system that can be used to assess 
the annual risk of stroke in AF [13]. The risk for stroke was calculated in 
this group of patients using CHADS2 score. Treatment with warfarin is 
recommended for a CHADS2 score of ≥2. Notably 22 patients had a risk 
of <2 of four. Demographic and clinical characteristic are demonstrated 
in Table 1.
Regarding the site of major bleeding during warfarin therapy, 
gastrointestinal bleeding (GIB) was most frequently reported, 19 
presented with clinical symptoms including of hemoptysis, black stool, 
and severe gum bleeding. Major bleeding at other sites was reported by 9 
patients, distributed as the following: Intraocular (n=3), intramuscular 
with compartment syndrome (n=3), renal  (n=1), intraarticular or 
pericardial (n=1) and intracranial (n=1) (Table 2).
The mean dose of warfarin was 3.1 mg, for the mean of 4.0±1.2 years. 
PT-INR value was calculated for each patient with major bleeding as 
the mean of all previous tests, including the one at time of admission. 
Notably, INR values for all patients were above the recommended range 
(2–3). The completed clinical characteristics of the case are presented 
in Table 2.
Only one patient had subdural intracranial hemorrhage, a Malay 
woman 46 years old, with a previous history of prosthetic valve and 
chronic heart failure, was admitted with severe headache, nausea, and 
vomiting for more than 4 days. The mean arterial pressure was 135/78 
(Table 3).
DISCUSSION
Long-term treatment with anticoagulation therapy is recommended 
stroke prophylaxis in patients diagnosed with AF [14,15]. However, 
treatment with warfarin is complicated due to the variability in the 
biological response to the drug [16,17], narrow therapeutic index, 
drug-food interactions [18,19], and the risk of thrombotic or bleeding 
events [6].
Table 2: Sites and frequencies of major bleeding events during 
warfarin therapy
Site of bleeding n (%)
Gastrointestinal 19 (67.9)
Intraocular 3 (10.7)
Intramuscular with compartment syndrome 3 (10.7)
Renal hemorrhage 1 (3.7)
Intracranial 1 (3.7)
Intra-articular or pericardial 1 (3.7)







More or equal 50×109 cells/L 15 (53.6)
≤50×109 cells/L 13 (46.4)
Table 1: Demographic and clinical characteristic of cases with 
major bleeding
Variables n (%)













Diabetes mellitus 9 (32.1)
Cerebrovascular disease 7 (25.0)
Coronary artery disease 4 (14.3)
Congestive heart failure 3 (10.7)
Prosthetic valve 3 (10.7)
Hyperlipidemia 3 (10.7)













Antiplatelets (aspirin or clopidogrel) 14 (50.0)
Digoxin 13 (46.4)
ACE inhibitors 15 (53.6)
Diuretics 11 (39.3)
Gastroprotective (H2-receptor blocker, PPI) 6 (21.4)
Calcium channel blockers 6 (21.4)
Angiotensin receptor blockers 3 (7.1)
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This study aimed at describing the frequency and sites of major bleeding 
events during warfarin therapy in patients with atrial fibrillation who 
admitted to PGH in Malaysia. The frequency of major bleeding was 1.7% 
which is lower than what was reported earlier as 10–16% [20,21]. 
GIB was the major site of bleeding which accounts for about 68% of 
the cases (n=17) [22,23]. This is in agreement with previous reports 
showing that the rate of GIB was 0–67%. In the present study, other 
sites of bleeding were presented with lower frequencies: 10.7% 
intraocular, 10.7% intramuscular with compartment syndrome, and 
only one case with either renal hemorrhage, intracranial, or intra-
articular hemorrhage.
Patients getting authorization of refills for their warfarin prescription 
is a common practice. However, monitoring in fact, a meta-analysis of 
five major studies for the primary prevention of stroke in AF patients 
in Western countries reported that thromboembolic events increased 
when PT-INR was <2.0, whereas hemorrhagic events became 
increasingly more frequent if PT-INR was ≥3.0 [24]. In this study, the 
average doses of warfarin used in the cases of major bleeding were 
3.1 mg; however, 96.3% of the cases had PT-INR value above 3 during 
the event of bleeding (recommended range is 2–3), which makes it the 
primary predictor of bleeding in those cases. This was not surprising 
because intensity of anticoagulation highly correlates with the risk of 
bleeding in warfarin patients in most studies [22,25,26]. To prevent 
the thromboembolic event while minimizing the risk of bleeding, 
an anticoagulation intensity at an INR of 2.0 could be an alternative 
anticoagulation strategy to traditional range, that is, 2.0–3.0.
It has been established earlier that ethnicity influences warfarin 
sensitivity. Several studies reported higher incidence of major 
bleeding among Asian population than in European countries and 
the US [27- 29], suggesting that lower doses are needed to achieve 
the target PT-INR [30]. This might be due to the variability in the 
biological response to warfarin or the average body mass index, which 
is considered small for Asian population [16,17].
It was noteworthy that the age in case of major bleeding was >65 years 
old, with a history of comorbidities, mainly hypertension and diabetes 
mellitus, the use of aspirin was recorded (INR value ≥3) in the majority 
of the cases. Previous studies showed that age, hypertension, diabetes 
mellitus, and the use of aspirin independent predictors of stroke 
associated with AF [23,31-35].
In this study, the most common cases of major bleeding fall in the age 
group with the range between 65 and 80 years old. Several mechanisms 
were proposed to increase the risk of bleeding in elderly patients, 
slow metabolism rate of warfarin, an elevated risk of drug interactions 
due to polypharmacy and chronic illnesses [36,37]. Whether older 
age increases the risk of bleeding in patients treated with warfarin is 
controversial [22]. However, it is well known that persons older than 80 
or 85 years of age do have a significant risk of bleeding [36]. Therefore, 
warfarin should be cautiously used in elderly patients, especially in 
extremely old patients. Recent guidelines recommend using lower 
intensity anticoagulation therapy in patients older than 65 years of 
age [38]. Concomitant use of proton-pump inhibitors significantly 
reduces the risk of GIB in patients treated with warfarin [39]. Therefore, 
acid suppressants may be considered in patients with a history of GIB 
during warfarin therapy.
The current guidelines recommend that the use of multiple 
therapy: Warfarin, aspirin, or clopidogrel is acceptable for short-
term treatment (up to 4 weeks) in patients with AF. Discontinuing 
of nonsteroidal anti-inflammatory drugs (NSAIDs) or adjusting 
warfarin dose should be considered if INR increases after starting the 
combination therapy [15,40]. A previous study in Malaysia identified 
peptic ulcer as the most common cause of admitted cases of GIB, and 
the use of NSAIDs being the major exacerbating factor [41]. Moreover, 
coadministration of medications with warfarin increases the risk of 
drug-drug interactions. All admitted patients with major bleeding 
were on fenofibrate therapy; an oral antilipidemic agent that has 
reported to response to warfarin by affecting coagulation factors 
synthesis (II, V, and VII) and inhibition of cytochrome P4503A4 
(CYP3A4) inhibitor liver enzyme [42]. Rigorous monitoring of the INR, 
at least 3 times per week, is recommended in case of concomitant use 
of warfarin and fenofibrate therapy. Patients are reluctant to undergo 
regular clinical assessment, and emerging risk factors of bleedings are 
often underreported several months after the initiation of warfarin 
therapy.
In Malaysia, warfarin has been the mainstay in patients with AF, who 
require anticoagulation therapy for the prevention of thrombosis. 
Anticoagulants use reduces the risk of having a stroke in patients with 
atrial fibrillation, but associated with various adverse effects, mainly 
bleeding events [7,8]. Monitoring of warfarin dose is mandatory in 
the first 3 months of therapy, given that major bleeding events occur 
more frequently during this period. Furthermore, interventions made 
by clinical pharmacists are successful in identifying and rectifying the 
different types of drug-related problems in patients with multiple drug 
use [43]. Community pharmacists may also contribute to the detection 
of adverse effects attributed to new medications uses and identify 
incorrect use of medicines [44].
Study limitations
First, the number of patients was rather small and the observation 
period was relatively short. Second, since the present study was 
retrospective, the incidence of bleeding could not be evaluated. 
Additional cohort large-scale clinical trials are required to develop the 
optimal control of anticoagulation therapy for the prevention of stroke 
among AF patients.
CONCLUSION
INR is the gold standard method of evaluating the risk of bleeding in 
patients taking warfarin. Lower doses of warfarin are recommended 
to achieve target PT-INR range similar to that reported for Asian 
populations. A regular clinical review for bleeding predictors is 
essential for maximizing the time spent by the patient taking warfarin 
in the optimal therapeutic range and for making recommended therapy 
adjustment.
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Table 3: Clinical characteristic of the intracranial hemorrhage 
case 
Type of intracranial hemorrhage Subdural
Computed tomography done? Yes
Magnetic resonance done? No
Mean arterial pressure 135/78
Clinical features of intracranial hemorrhage Hemiparesis
Estimated time from onset of symptoms to 
presentation
>7 days
CT scan: Size of hematoma 0.5
CT scan: Location of hematoma Subdural hematoma 
(cerebral edema)
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